Teclistamab(SC)

DRUG2 trials

Conditions

Hematological MalignanciesSevere Rapidly Progressive Interstitial Lung Disease Associated With Anti-MDA5

Phase 1

Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma

Active, not recruitingNCT03145181

Janssen Research & Development, LLCHematological Malignancies

Start: 2017-05-16End: 2027-08-24Updated: 2026-08-28

Phase 2

Study of the Efficacy and Safety of a Bispecific Antibody, Teclistamab in Severe Rapidly Progressive Interstitial Lung Disease Associated With Anti-MDA5

Not yet recruitingNCT07631208

Assistance Publique - Hôpitaux de ParisSevere Rapidly Progressive Interstitial Lung Disease Associated With Anti-MDA5

Start: 2026-10-30End: 2027-01-01Target: 24Updated: 2026-06-05

eJHaem2026-07-30

Longitudinal mechanisms of response, resistance and relapse to teclistamab in multiple myeloma: results from MajesTEC-1.

2026-06-11

Revised Recommendations for Restarting Teclistamab Following Dose Delays: Insights from the MajesTEC-1 Study on Clinical Safety, and from Simulated Pharmacokinetics and Cytokine Dynamics

Targeted Oncology2026-03-26

Efficacy and safety of teclistamab in triple-class exposed relapsed/refractory multiple myeloma: Pooled findings from three clinical cohorts and a retrospective cohort.

2026-01-01

Cost per responder for teclistamab and elranatamab in relapsed or refractory multiple myeloma in the United States.

2025-06-14

Matching-Adjusted Indirect Comparison of Elranatamab versus Teclistamab in Patients with Triple-Class Exposed/Refractory Multiple Myeloma: Updated Results.

2025-05-14

Teclistamab Dosing in Responders: Modeling and Simulation Results from the MajesTEC-1 Study in Relapsed/Refractory Multiple Myeloma.

2025-05-072 citations

Efficacy, safety, and pharmacokinetics of teclistamab in Chinese patients with relapsed/refractory multiple myeloma from the China cohort of MajesTEC‐1

Cancer2024-12-116 citations

Optec: A Phase 2 Study to Evaluate Outpatient Step-up Administration of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results

Blood2024-11-055 citations

Analysis of Repeat Step-up Dosing and Cytokine Release Syndrome Events Following Prolonged Dosing Intervals of Teclistamab in the Phase 1/2 Majestec-1 Study

Blood2024-11-054 citations

Less Frequent Teclistamab Dosing in Responders: Modeling and Simulation Data from the Majestec-1 Study in Relapsed/Refractory Multiple Myeloma

Blood2024-11-052 citations

Pooled Efficacy and Safety of Teclistamab in 217 Patients with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma from 3 Registrational Clinical Studies

Blood2024-11-051 citations

LONG-TERM FOLLOW-UP FROM THE PHASE 1/2 MAJESTEC-1 TRIAL OF TECLISTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: SUBGROUP ANALYSIS BY LINES OF THERAPIES

Hematology Transfusion and Cell Therapy2024-10-012 citations

Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies

Blood2024-08-2236 citations

Long-term follow-up from the phase 1/2 MajesTEC-1 trial of teclistamab in patients with relapsed/refractory multiple myeloma.

Journal of Clinical Oncology2024-06-0154 citations

Safety results from the phase 3 MajesTEC-7 study in patients (pts) with transplant ineligible/not intended newly diagnosed multiple myeloma (NDMM).

Journal of Clinical Oncology2024-06-0114 citations

Longer-term follow-up of patients (pts) receiving prophylactic tocilizumab (toci) for the reduction of cytokine release syndrome (CRS) in the phase 1/2 MajesTEC-1 study of teclistamab in relapsed/refractory multiple myeloma (RRMM).

Journal of Clinical Oncology2024-06-0112 citations

Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in the MajesTEC-1 study

Blood2024-04-2436 citations

A matching-adjusted indirect comparison of the efficacy of elranatamab versus teclistamab in patients with triple-class exposed/refractory multiple myeloma

Leukemia & lymphoma/Leukemia and lymphoma2024-02-1212 citations

Comparative Effectiveness of Teclistamab Versus Real-World Physician's Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma.

2023-12-195 citations

31 more papers not shown

Teclistamab(SC)

Sponsors

Conditions

Phase 1

Phase 2

Related Papers